Laser in situ keratomileusis for hyperopia and hyperopic astigmatism with the Nidek EC-5000 excimer laser

A. Pineda-Fernández, L. Rueda, David Huang, J. Nur, J. Jaramillo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

PURPOSE: We evaluated the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) for hyperopia and hyperopic astigmatism. METHODS: A retrospective study was performed for 92 eyes of 62 consecutive patients to evaluate uncorrected (UCVA) and best spectacle-corrected visual acuity (BSCVA) and manifest refraction before and 3 and 6 months after LASIK (Moria LSK-ONE microkeratome, Nidek EC-5000 excimer laser). Eyes were divided into groups: Group 1 (low hyperopia) for spherical correction of +1.00 to +3.00 D (22 eyes), Group 2 (low hyperopic astigmatism) for toric correction with spherical equivalent refraction of +1.00 to +3.00 D (18 eyes), Group 3 (moderate hyperopia) for spherical correction of +3.25 to +6.00 D (10 eyes), and Group 4 (moderate hyperopic astigmatism) for toric correction with spherical equivalent refraction between +3.25 and +6.00 D (18 eyes). RESULTS: At 3 and 6 months after LASIK, 68 eyes (73.9%) were available for follow-up examination. Percentage of eyes with a spherical equivalent refraction within ±0.50 D of emmetropia for Group 1 was 54.5% (12 eyes); Group 2, 50% (9 eyes); Group 3, 40% (4 eyes), and Group 4, 38.8% (7 eyes). UCVA ≥20/20 in Group 1 was 14% and in Groups 2, 3, and 4, 0%. One eye (5.5%) lost two lines of BSCVA. CONCLUSION: LASIK with the Moria LSK-ONE microkeratome and the Nidek EC-5000 excimer laser reduced low and moderate hyperopia and was within ±0.50 D of target outcome in approximately 50% of eyes. Undercorrection was evident in all groups. The procedure was safe.

Original languageEnglish (US)
Pages (from-to)670-675
Number of pages6
JournalJournal of Refractive Surgery
Volume17
Issue number6
StatePublished - 2001
Externally publishedYes

Fingerprint

Hyperopia
Excimer Lasers
Laser In Situ Keratomileusis
Astigmatism
Visual Acuity
Emmetropia

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Laser in situ keratomileusis for hyperopia and hyperopic astigmatism with the Nidek EC-5000 excimer laser. / Pineda-Fernández, A.; Rueda, L.; Huang, David; Nur, J.; Jaramillo, J.

In: Journal of Refractive Surgery, Vol. 17, No. 6, 2001, p. 670-675.

Research output: Contribution to journalArticle

Pineda-Fernández, A. ; Rueda, L. ; Huang, David ; Nur, J. ; Jaramillo, J. / Laser in situ keratomileusis for hyperopia and hyperopic astigmatism with the Nidek EC-5000 excimer laser. In: Journal of Refractive Surgery. 2001 ; Vol. 17, No. 6. pp. 670-675.
@article{3e9de6a553754be18869476957faa946,
title = "Laser in situ keratomileusis for hyperopia and hyperopic astigmatism with the Nidek EC-5000 excimer laser",
abstract = "PURPOSE: We evaluated the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) for hyperopia and hyperopic astigmatism. METHODS: A retrospective study was performed for 92 eyes of 62 consecutive patients to evaluate uncorrected (UCVA) and best spectacle-corrected visual acuity (BSCVA) and manifest refraction before and 3 and 6 months after LASIK (Moria LSK-ONE microkeratome, Nidek EC-5000 excimer laser). Eyes were divided into groups: Group 1 (low hyperopia) for spherical correction of +1.00 to +3.00 D (22 eyes), Group 2 (low hyperopic astigmatism) for toric correction with spherical equivalent refraction of +1.00 to +3.00 D (18 eyes), Group 3 (moderate hyperopia) for spherical correction of +3.25 to +6.00 D (10 eyes), and Group 4 (moderate hyperopic astigmatism) for toric correction with spherical equivalent refraction between +3.25 and +6.00 D (18 eyes). RESULTS: At 3 and 6 months after LASIK, 68 eyes (73.9{\%}) were available for follow-up examination. Percentage of eyes with a spherical equivalent refraction within ±0.50 D of emmetropia for Group 1 was 54.5{\%} (12 eyes); Group 2, 50{\%} (9 eyes); Group 3, 40{\%} (4 eyes), and Group 4, 38.8{\%} (7 eyes). UCVA ≥20/20 in Group 1 was 14{\%} and in Groups 2, 3, and 4, 0{\%}. One eye (5.5{\%}) lost two lines of BSCVA. CONCLUSION: LASIK with the Moria LSK-ONE microkeratome and the Nidek EC-5000 excimer laser reduced low and moderate hyperopia and was within ±0.50 D of target outcome in approximately 50{\%} of eyes. Undercorrection was evident in all groups. The procedure was safe.",
author = "A. Pineda-Fern{\'a}ndez and L. Rueda and David Huang and J. Nur and J. Jaramillo",
year = "2001",
language = "English (US)",
volume = "17",
pages = "670--675",
journal = "Journal of Refractive Surgery",
issn = "0883-0444",
publisher = "Slack Incorporated",
number = "6",

}

TY - JOUR

T1 - Laser in situ keratomileusis for hyperopia and hyperopic astigmatism with the Nidek EC-5000 excimer laser

AU - Pineda-Fernández, A.

AU - Rueda, L.

AU - Huang, David

AU - Nur, J.

AU - Jaramillo, J.

PY - 2001

Y1 - 2001

N2 - PURPOSE: We evaluated the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) for hyperopia and hyperopic astigmatism. METHODS: A retrospective study was performed for 92 eyes of 62 consecutive patients to evaluate uncorrected (UCVA) and best spectacle-corrected visual acuity (BSCVA) and manifest refraction before and 3 and 6 months after LASIK (Moria LSK-ONE microkeratome, Nidek EC-5000 excimer laser). Eyes were divided into groups: Group 1 (low hyperopia) for spherical correction of +1.00 to +3.00 D (22 eyes), Group 2 (low hyperopic astigmatism) for toric correction with spherical equivalent refraction of +1.00 to +3.00 D (18 eyes), Group 3 (moderate hyperopia) for spherical correction of +3.25 to +6.00 D (10 eyes), and Group 4 (moderate hyperopic astigmatism) for toric correction with spherical equivalent refraction between +3.25 and +6.00 D (18 eyes). RESULTS: At 3 and 6 months after LASIK, 68 eyes (73.9%) were available for follow-up examination. Percentage of eyes with a spherical equivalent refraction within ±0.50 D of emmetropia for Group 1 was 54.5% (12 eyes); Group 2, 50% (9 eyes); Group 3, 40% (4 eyes), and Group 4, 38.8% (7 eyes). UCVA ≥20/20 in Group 1 was 14% and in Groups 2, 3, and 4, 0%. One eye (5.5%) lost two lines of BSCVA. CONCLUSION: LASIK with the Moria LSK-ONE microkeratome and the Nidek EC-5000 excimer laser reduced low and moderate hyperopia and was within ±0.50 D of target outcome in approximately 50% of eyes. Undercorrection was evident in all groups. The procedure was safe.

AB - PURPOSE: We evaluated the efficacy, predictability, stability, and safety of laser in situ keratomileusis (LASIK) for hyperopia and hyperopic astigmatism. METHODS: A retrospective study was performed for 92 eyes of 62 consecutive patients to evaluate uncorrected (UCVA) and best spectacle-corrected visual acuity (BSCVA) and manifest refraction before and 3 and 6 months after LASIK (Moria LSK-ONE microkeratome, Nidek EC-5000 excimer laser). Eyes were divided into groups: Group 1 (low hyperopia) for spherical correction of +1.00 to +3.00 D (22 eyes), Group 2 (low hyperopic astigmatism) for toric correction with spherical equivalent refraction of +1.00 to +3.00 D (18 eyes), Group 3 (moderate hyperopia) for spherical correction of +3.25 to +6.00 D (10 eyes), and Group 4 (moderate hyperopic astigmatism) for toric correction with spherical equivalent refraction between +3.25 and +6.00 D (18 eyes). RESULTS: At 3 and 6 months after LASIK, 68 eyes (73.9%) were available for follow-up examination. Percentage of eyes with a spherical equivalent refraction within ±0.50 D of emmetropia for Group 1 was 54.5% (12 eyes); Group 2, 50% (9 eyes); Group 3, 40% (4 eyes), and Group 4, 38.8% (7 eyes). UCVA ≥20/20 in Group 1 was 14% and in Groups 2, 3, and 4, 0%. One eye (5.5%) lost two lines of BSCVA. CONCLUSION: LASIK with the Moria LSK-ONE microkeratome and the Nidek EC-5000 excimer laser reduced low and moderate hyperopia and was within ±0.50 D of target outcome in approximately 50% of eyes. Undercorrection was evident in all groups. The procedure was safe.

UR - http://www.scopus.com/inward/record.url?scp=0035200727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035200727&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 670

EP - 675

JO - Journal of Refractive Surgery

JF - Journal of Refractive Surgery

SN - 0883-0444

IS - 6

ER -